Akademik Veri Yönetim Sistemi
ACTA POLONIAE PHARMACEUTICA, cilt.75, sa.1, ss.141-153, 2018 (SCI-Expanded)
The aim of this study was to prepare a new thermosensitive in situ gel formulation of flurbiprofen for ocular delivery to increase the precomeal residence time and to prolong the drug release. Flurbiprofen loaded PLGA nanoparticles were prepared by the nanoprecipitation method. After physicochemical characterization studies, the cytotoxicity profile of the nanoparticles was investigated on human cornea epithelial cells. Anti-inflammatory activity of nanoparticles were also evaluated. Selected nanoparticle formulation was incorporated in a temperature-triggered in situ gelling system. In vitro drug release studies of the in situ gel formulations containing nanoparticles or pure flurbiprofen were carried out using the dialysis bag method. The cell viability ratios were found to be higher than 85% for the selected FN5 and FN7 coded nanoparticle formulations. According to these results, it was estimated that the flurbiprofen-loaded PLGA nanoparticles had no toxic effects on the human cornea epithelial cells. The COX inhibition rate of the FNS-coded formulation was also higher than that of the commercial product and flurbiprofen solution. On the other hand, the prolonged release of flurbiprofen was obtained with themsosensitive in situ gel formulations compared to the commercial product of the drug. The in situ gel formulation containing PLGA nanoparticles seems to be a promising alternative drug delivery system to the conventional dosage form of flurbiprofen.